Predilife S.A. announced that it is partnering with the Institut Curie for the launch of the next-generation of MammoRisk®, that incorporates a polygenic score based on a saliva sample. Designed for prescription by doctors, MammoRisk® is a test complementing mammograms that predicts the risk of breast cancer by taking into account 5 risk factors: the patient’s age, breast density, family history breast biopsy history and a polygenic score calculated using the latest scientific publications. This score is the product of analysis of hundreds of thousands of genome variations, polymorphisms or SNPs. These common variations in the general population are polymorphisms. Some of these polymorphisms have been associated with a higher risk of breast cancer. On their own, these polymorphisms have a low impact, but certain combinations of them have a major impact on the risk of breast cancer, comparable to other well-known factors, such as breast density and family history. The partnership between PrediLife and the Institut Curie will initially study around a hundred polymorphisms associated with a higher risk of breast cancer, with the Institut Curie performing the genetic analyses incorporated in the MammoRisk® score. Subsequently, PrediLife and the Institut Curie will pursue research projects by capitalizing on the tight fit between the breast cancer expertise of the Institut Curie, Europe’s center for the treatment of women with cancer, and PrediLife’s ability to develop and market these tests.